Physician profile
Walter Ryan
NPI 1073503843
$7,601.38
in general payments reported to CMS, 2019-2025
27 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $374 · 2021: $3,438 · 2022: $1,957 · 2023: $829 · 2024: $93.26 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.34 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $2,396.75 | 2019-2023 | Ruconest |
| Glaxosmithkline, LLC. | $1,480.97 | 2019-2023 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $951.38 | 2019-2024 | Airsupra, Tezspire, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $408.91 | 2020-2023 | Hyqvia |
| Regeneron Healthcare Solutions, INC. | $307.05 | 2019-2025 | Dupixent |
| Optinose US, INC. | $273.56 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.43 | 2019-2022 | |
| Pfizer INC. | $252.16 | 2019-2023 | |
| Genzyme Corporation | $187.15 | 2019-2023 | |
| Incyte Corporation | $174.99 | 2021-2022 | |
| Csl Behring | $122.37 | 2019-2022 | |
| Genentech USA, INC. | $116.03 | 2019-2023 | Xolair |
| Alk-Abello, INC | $110.54 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $89.40 | 2019-2023 | |
| Amgen INC. | $88.82 | 2021-2023 | Tezspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $74.66 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $56.39 | 2021 | |
| Kaleo, INC. | $46.11 | 2021 | |
| Shire North American Group INC | $42.18 | 2019 | |
| Octapharma USA, INC. | $28.62 | 2022 | |
| Aimmune Therapeutics, INC. | $27.96 | 2021 | |
| Ionis Pharmaceuticals, INC. | $25.00 | 2025 | |
| Horizon Therapeutics Plc | $20.00 | 2020 | |
| Merck Sharp & Dohme LLC | $18.49 | 2021 | |
| Sunovion Pharmaceuticals INC. | $17.29 | 2019 | |
| Uswm, LLC | $16.00 | 2021 | |
| Blueprint Medicines Corporation | $15.17 | 2023 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.